Main Article Content
Abstract
Type 2 diabetes mellitus (T2DM) requires regular evaluation of glycemic control, yet local evidence comparing insulin-containing and oral antidiabetic drug (OAD) regimens in routine care remains limited. This study compared the six-month change in glycated hemoglobin (HbA1c) and fasting blood glucose (FBG) between outpatients receiving OAD alone and outpatients receiving insulin combined with OAD. Because treatment was allocated by clinical indication rather than at random, the study describes treatment-associated glycemic change and does not establish causal treatment effects. An analytical observational study with a retrospective comparative design used medical records from the Internal Medicine Clinic of Universitas Sebelas Maret Hospital, Surakarta, Indonesia. Fifty-four patients were selected by purposive sampling (OAD, n = 27; insulin plus OAD, n = 27) and followed for six months. The primary endpoint was the between-group difference in ΔHbA1c and the secondary endpoint the between-group difference in ΔFBG, tested with the Mann–Whitney U test and summarized as a rank-biserial correlation (r) with 95% confidence intervals (CI); within-group change was tested with the Wilcoxon signed-rank test. Most patients were female (53.7%) and had comorbidities (94.4%). Mean HbA1c fell from 8.45% to 7.14% in the OAD group (p = 0.005) and from 10.46% to 9.21% in the insulin group (p = 0.115), while FBG fell from 146.19 to 129.44 mg/dL (p = 0.089) and from 187.56 to 173.96 mg/dL (p = 0.614), respectively. Baseline and six-month values were significantly higher in the insulin group (all p < 0.05). No statistically significant between-group difference in change was detected for HbA1c (difference in mean change +0.06 percentage points; rank-biserial r = 0.03; 95% CI −0.29 to 0.34; p = 0.869) or FBG (+3.15 mg/dL; r = 0.05; 95% CI −0.27 to 0.36; p = 0.775). These intervals are wide and do not establish equivalence between the regimens. Patients receiving insulin began and remained further from target, supporting structured follow-up and timely treatment intensification.
Keywords
Article Details
Copyright (c) 2026 Gema Lingkungan Kesehatan

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.